Liquid Biopsy Market Analysis-2020


Posted July 17, 2020 by SANJAYCMI

“Coherent Market Insights “LIQUID BIOPSY MARKET – GLOBAL TRENDS, ESTIMATES AND FORECASTS, 2020-2027″
 
The global liquid biopsy market is estimated to accumulate over US$ 3,535.1 million, in terms of value, by the end of 2027.

Of the two different test categories for liquid biopsies, one is based on the type of material analyzed in the test, while the other is based on the type of analysis that is performed to detect or monitor cancer. On the basis of material type, the global liquid biopsy market can be segmented into analysis of tumor cells, analysis of free DNA, analysis of Exosomal DNA, and analysis of miRNAs. Moreover, based on the analysis type, the global market can be fragmented into small-scale mutation analysis and targeted deep sequencing, analysis of structural changes, large-scale mutation analysis by next-generation sequencing, and analysis of copy number alterations.

Rising inclination towards non-invasive diagnostic procedures is a vital factor expected to boost the global liquid biopsy market growth over the forecast period. Liquid biopsy offers non-invasive diagnostic tests for detecting cancer. It results in lower morbidity compared to conventional biopsy. Moreover, liquid biopsy can offer a better insight of all the tumor profiles and genetic mutations in a patient.

Browse Research Report: https://www.coherentmarketinsights.com/market-insight/liquid-biopsy-market-1223

Hence, cooperation among bioinformatics specialists, biochemists, and physicians enhances the adoption of liquid biopsy across the globe. Parallel investigation of conventional biopsy and liquid biopsy is required to assess the efficacy of liquid biopsy in diagnosis of cancer.
However, access to a limited number of genes acts as a major hindrance for the growth of the global market. Tissue biopsy allows oncologists and doctors to assess multiple genes simultaneously. However, in liquid biopsy, blood and urine tests provides access to one gene at a time, which might not provide accurate companion diagnosis to start the treatment.

Market Trends:
The CTC (Circulating Tumor Cells) segment in the global liquid biopsy market had acquired US$ 416.7 million in 2019, and is now estimated to reach US$ 1,710.8 million by 2027 at a CAGR of 19.3% during the forecast period. Increasing prevalence of cancer is a major factor propelling growth of the global liquid biopsy market over the forecast period.

To learn more about this report, request a sample copy*
* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/1223

The blood sample segment led the global liquid biopsy market in 2019, accumulating a 93.6% share, in terms of value. Growing preference for non-invasive diagnostic procedures would potentially propel the growth of the global liquid biopsy market in the foreseeable future.
The adoption of Artificial Intelligence (AI) in liquid biopsy is rapidly increasing. For instance, Freenome, an AI genomics company based in the U.S., is focused on developing blood tests to detect the body’s early-warning signs of cancer, using AI. In October 2018, the company presented early data in R&D for using machine learning to detect colorectal cancer at its earliest stages.

Competitive Backdrop:
The well-known companies operating in the global liquid biopsy market include Biocept, Inc., Qiagen N.V., Trovagene, Inc., Janssen Global Services, LLC, MDxHealth SA, Natera, Inc., F. Hoffmann-La Roche Ltd., Silicon Biosystems, Pathway Genomics Corporation, and Sysmex Corporation.
In February 2020, QIAGEN N.V launched its FFPE and liquid biopsy PIK3CA diagnostics in Europe as an aid in identifying breast cancer patients with a phosphatidyl 3-kinase catalytic subunit alpha (PIK3CA) mutation. Furthermore, in January 2020, Zomedica Pharmaceuticals Corp., a veterinary diagnostic and pharmaceutical company, announced completing the development and manufacturing of its reference lab cancer liquid biopsy platform for canine cancers.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/1223

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
[email protected]
U.S. Office:
Name: Mr. Shah
Coherent Market Insights 1001 4th Ave,
# 3200 Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By Coherent Market Insights
Phone +1-206-701-6702
Business Address 1001 4th Ave
# 3200 Seattle, WA 98154, U.S.
Country United States
Categories Health , Marketing , Research
Tags liquid biopsy market , liquid biopsy market analysis , liquid biopsy market share
Last Updated July 17, 2020